MicroPort Scientific Corporation Announces HKEx Main Board Listing Details

Transcription

1 MicroPort Scientific Corporation Announces HKEx Main Board Listing Details ******************************************************** Global Offering of 252,740,000 Shares At between HK$4.60 and HK$6.10 Per Share HONG KONG, 12 September 2010 MicroPort Scientific Corporation ( MicroPort or the Company ), a leading developer, manufacturer and marketer of medical devices in China minimally invasive interventional products for the treatment of vascular diseases and disorders, today announced the details of its proposed listing on the Main Board of The Stock Exchange of Hong Kong Limited ( HKEx ). MicroPort will offer a total of 252,740,000 shares under the Global Offering comprising, initially, 25,274,000 shares being offered to the public in Hong Kong for subscription under the Hong Kong Public Offering, and 227,466,000 shares under the International Offering, subject to adjustment and the over-allotment option. The Company expects grant to the underwriters under the International Underwriting Agreement an over-allotment option to allot and issue up to an aggregate of 37,911,000 additional shares, representing up to 15% of the initial size of the Global Offering. The offer price range will be between HK$4.60 and HK$6.10 per share. At the mid-point of the indicative offer price range, the Company s net proceeds of the Global Offering would be approximately HK$1,246.9 million before exercise of the over-allotment option. Credit Suisse (Hong Kong) Limited is the Sole Global Coordinator. Credit Suisse (Hong Kong) Limited and Piper Jaffray Asia Limited are the Joint Sponsors. Credit Suisse (Hong Kong) Limited and Piper Jaffray Asia Securities Limited are Joint Bookrunners and Joint Lead Managers of the Global Offering. The Hong Kong Public Offering will open at 9 am on Monday, 13 September 2010 and close at 12 noon on Thursday, 16 September The offer price is expected to be determined on Friday, 17 September 2010 and allotment results will be announced on Wednesday, 22 September Trading of the Company s shares on the HKEx is expected to commence on Friday, 24 September 2010 under the stock code 853. Shares will be traded in board lots of 1,000 shares. 1

2 Use of Proceeds Approximately 50% of the net proceeds will be allocated to expand MicroPort s product offerings including enhancing its research and development such as conducting clinical trials and obtaining domestic and international regulatory approvals. The Company will also focus on developing new product lines to diversify its business as well as acquiring businesses or licensing products or technologies that are complementary to its existing capabilities. Approximately 25% of the net proceeds will be used to expand its production facilities which will include expansion of its manufacturing facilities to be completed in 2012 with an estimated annual production capacity of approximately 700,000 to 1,000,000 units of stents and catheters. Approximately 20% of the net proceeds will be used to expand the Company s sales, marketing and distribution activities in China and worldwide in particular the Asia Pacific region and Europe by expanding the sales, marketing and distribution network, enhancing the brand name and market position as well as increasing training and education of physicians. The remaining 5% of the net proceeds will be used to fund working capital and for other general corporate purposes. A Leading Provider of Minimally Invasive Products in China MicroPort is a leading provider focusing primarily on minimally invasive interventional products for the treatment of vascular diseases and disorders. According to Frost & Sullivan, MicroPort is the No. 1 provider of coronary stents, accounting for approximately 26.6%, 28.7% and 28.9% of all coronary stents implanted in China in 2007, 2008 and 2009 respectively. The Company is also the first China-based company to manufacture interventional cardiovascular products and to develop Drug-Eluting Stents ( DES ) commercially. Leveraging its experienced research and development team, MicroPort internally developed and commercialized almost all of its 18 cardiovascular, other vascular devices as well as an EP and a diabetes device with strong brand recognition. Its principal product Firebird 2, the second generation drug-eluting cobalt-chromium stent, and its predecessor Firebird, have been the leaders in China s drug-eluting stents market. In addition to the Firebird line, the Company s product offerings includes a range of other vascular stents to treat vascular diseases and disorders in other parts of the body, intracranial stents used to facilitate blood flow in blood vessels in the brain and stent grafts for use in surgical operations. Building on its extensive experience in clinical trials and commercialization of new products, MicroPort had an additional 28 products in various stages of development and have 2

3 amassed a large intellectual property portfolio. The Company had received a total of 52 patents in China while having 83 patent applications pending in China and 11 patent applications pending in the United States, the European Union and Japan. In addition to next-generation stents, the Company leveraged its strong research and development capabilities to develop medical devices for other chronic ailments including a new electrophysiology ( EP ) catheter product called FireMagic and insulin pump, La Fenice. More EP and diabetes-related products are under development. The Company is also working on a range of orthopedic devices for the treatment of orthopedic disorders as a result of injury and aging. Due to early entry into the minimally invasive interventional device market in China,, MicroPort has an established network with key opinion leaders in the Chinese medical community. Through its own direct sales and marketing teams and a nationwide network of 125 independent distributors, MicroPort s products have been used in over 1,100 hospitals across China during 2007 to Furthermore, its products are sold to more than 20 countries in Asia, South America and Europe. MicroPort s advanced manufacturing facilities are among the largest of any interventional medical device company in China. The facilities, located in Shanghai, cover the integrated production processes and serves as a high quality and cost-effective manufacturing platform enabling us to price its products competitively while maintaining high quality standards. Dr. Zhaohua CHANG, founder, Executive Director and Chairman of MicroPort said, As a successful China-based manufacturer, our proven efficacy, high precision manufacturing and advanced technology have established high entry barriers amongst our competition. MicroPort s products, with highly competitive pricing against foreign brand names while offering comparable quality have gained strong recognition among doctors and hospitals. These unique advantages will continue to drive our growth. MicroPort has a proven track record of commercializing its products and delivering strong financial performance. Revenue of MicroPort grew from around RMB421.3 million in 2007 to RMB560.7 million in For the three months ended March 31, 2009 and 2010, the Company had recorded revenue of RMB137.6 million and RMB176.7 million, respectively, representing an increase of 28.5%. Its net profit increased from RMB102.2 million in 2007 to RMB186.4 million in Barring unforeseen circumstances, the Company estimates that its profit after taxation ended 30 June, 2010 will not be less than RMB 140 million. Increasing government spending and new healthcare initiatives in China have improved patient s accessibility and affordability of medical care which led to more diagnosis and treatment of chronic diseases. According to Frost & Sullivan, the coronary stent market is expected to grow to approximately RMB17 billion in 2014 given the increasing prevalence 3

4 of cardiovascular diseases in China. China s healthcare industry is expected to grow with expanded basic medical insurance coverage and addition of 2,000 county hospitals and approximately 30,000 township hospitals by MicroPort is committed to capitalize on this growth with its focused business strategy. Building on our leadership position, we shall continue to enhance MicroPort s brand and market position in China, broadening our product portfolio and developing new technologies to prepare for entry into complementary medical devices market. We shall leverage our core strengths to further expand our brand awareness and sales internationally and pursue product and technology purchase opportunities, strategic acquisitions and alliances. Looking ahead, our experienced management and dedicated staff will continue to work hard in order to maximize return to shareholders, added Dr. CHANG. Where to collect the Application Forms: For the Hong Kong Public Offer, white Application Forms and Prospectuses can be obtained from any of the Hong Kong Underwriters, including - Credit Suisse (Hong Kong) Limited - Piper Jaffray Asia Securities Limited or any of the designated branches of Bank of China (Hong Kong) Limited and Standard Chartered Bank (Hong Kong) Limited. Applicants may also complete electronic applications under Hong Kong eipo White Form service through the designated website Yellow Application Forms can be obtained from Hong Kong Securities Clearing Company Limited or from the applicant's stockbroker, who may have such Application Forms and Prospectuses available. Company photos (Please click below link to download) This document does not constitute and is not an offer to sell or a solicitation of an offer to buy securities (the securities ) of MicroPort Scientific Corporation (the Company ) in the United States. The securities have not been registered under the US securities Act of 1933, as amended (The US Securities Act ) and may not be offered or sold in United States absent registration under the US Securities Act or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and will contain information about the Company s management, as well as financial statements. The Company does not intend to make any public offering of the securities in the United States. #### 4

5 For further enquiries, please contact Hill & Knowlton Asia Ltd:- Carol Mak Jacqueline Lee Tel: (852) / Tel: (852) / carol.mak@hillandknowlton.com.hk jacqueline.lee@hillandknowlton.com.hk 5

6 MicroPort Scientific Corporation Offering Statistics No. of Offer Shares No. of International Offer Shares No. of Hong Kong Public Offer Shares Offer Price Range Market Capitalization Dealings Expected to Commence 252, 740,000 Shares (Subject to the over-allotment option) 227,466,000 Shares* (Subject to adjustment and the over-allotment option) 25,274,000 Shares (Subject to adjustment) HK$4.60 to HK$6.10 per Share Approx. HK$6,458.9 million to HK$8,565.1 million (Before exercise of the over-allotment option) 24 September 2010 (Friday) Stock Code 853 Board Lot 1,000 Shares * The Company may allot and issue up to an aggregate of 37,911,000 additional Shares pursuant to the over-allotment option. 6